Skip to main content
OpenTrials
Completed

NCT Number: NCT00999141

Efficacy and Safety of FS VH S/D 4 S-apr for Flap Adherence in Rhytidectomy

The purpose of the study is to compare the safety and efficacy of FS VH S/D 4 s-apr versus standard of care in adhering tissue and improving wound healing in subjects undergoing facelift.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Face-lift Facial Rhytidectomy

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Beverly Hills, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female subject is 18 to 75 years of age at the time of screening
  • Subject is planned for facial rhytidectomy
  • Subject has read, understood and signed the written informed consent
  • Subject is healthy, as determined by the investigator using standard pre-operative assessments to include laboratory tests and electrocardiograms
  • Subject is of childbearing potential, presents with a negative serum pregnancy test, and agrees to employ adequate birth control measures for the duration of the study
  • Subject is willing and able to comply with the requirements of the protocol

Exclusion criteria

  • Subject is indicated for an abbreviated or modified face-lift procedure such as deep plane procedures, minimal undermining procedures, thread lifts, and minimal access cranial suspension
  • Subject is indicated for concurrent facial surgeries during the operation (eg forehead plasty,blepharoplasty, rhinoplasty, buccal fat removal, any filler injections including fat injections, lip augmentation, skin resurfacing procedures etc.)
  • Subject is indicated for additional procedures to the body during the same operation (eg liposuction, mastoplasty etc.)
  • Subject has undergone a prior rhytidectomy surgery
  • Subject is an active smoker, as assessed by the investigator
  • Subject has a known (documented) bleeding or coagulation disorder
  • Subject is being treated with anti-coagulants or with Aspirin (that was not discontinued 7 days prior to surgery)
  • Subject has a vascular disorder, cardiovascular disease, and/or uncontrolled hypertension
  • Subject has diabetes mellitus with glycosylated hemoglobin (HbA1c) > 7
  • Subject is receiving active treatment for a malignancy
  • Subject has a connective tissue disorder
  • Subject has an active or chronic skin disorder
  • Subject has history of Bell's palsy
  • Subject has a documented history of pathologically or pharmacologically induced immune deficiency
  • Subject has received chronic treatment with immunosuppressive drugs, systemic corticosteroids, or other chronic treatments within 30 days prior to the surgery
  • Subject has a known sensitivity to components of FS VH S/D 4 s-apr
  • Subject has a known psychiatric disorder (eg, obsessive compulsive disorder, anxiety, eating disorders, etc.)
  • Subject has documented healing complications following previous surgeries (eg, hypertrophic scarring)
  • Subject is pregnant or lactating at the time of enrollment
  • Subject has participated in another clinical study involving an investigational product/device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an investigational product/device during the course of this study

Treatment and study plan

FS VH S/D 4 s-apr

Biological

FS VH S/D 4 s-apr will be applied (using spray device provided by Sponsor) to the subcutaneous plane (intraoperative, topical administration) in both the neck and the face area.

Other names: ARTISS

Primary outcomes

  1. Total Volume of Drainage on Each Side of the Face

    Time frame: 24 hours (± 4h) after surgery

    Total drainage volume collected from each side of the face. One side of face is treated with FS VH S/D 4 s-apr (FS); the other side is treated using standard of care (SoC).

  2. Number of AEs Related to the Investigational Product (FS VH S/D 4 S-apr)

    Time frame: Day 0 (day of surgery) through postoperative Day 14

Secondary outcomes

  1. Participants' First Occurrence of Hematoma or Seroma by Study Day

    Time frame: Day 0 (day of surgery) through postoperative day 14

    Investigators assessed each side of the face for the presence of hematomas and/or seromas

  2. Participants With Hematoma/Seroma by Study Day

    Time frame: Day 0 (day of surgery) through postoperative day 14

    Investigators assessed each side of the face for the presence of hematoma and/or seroma

  3. Number of Participants With Hematoma/Seroma Anytime During the Study

    Time frame: Day 0 (day of surgery) through postoperative Day 14

  4. Investigators' Visual Comparisons of Edema Between the 2 Sides of Face at Day 1

    Time frame: Through postoperative Day 1

    Investigators' assessed which side of the face (FS VH S/D 4 s-apr or Standard SoC) had less edema

  5. Investigators' Visual Comparisons of Edema Between the 2 Sides of Face at Day 3

    Time frame: Through postoperative Day 3

    Investigators' assessed which side of the face (FS VH S/D 4 s-apr or Standard SoC) had less edema

  6. Investigators' Visual Comparisons of Edema Between the 2 Sides of Face at Day 7

    Time frame: Through postoperative Day 7

    Investigators' assessed which side of the face (FS VH S/D 4 s-apr or Standard SoC) had less edema

  7. Investigators' Visual Comparisons of Edema Between the 2 Sides of Face at Day 14

    Time frame: Through postoperative Day 14

    Investigators' assessed which side of the face (FS VH S/D 4 s-apr or Standard SoC) had less edema

  8. Change From Baseline (Day 0, Preoperative) in Skin Sensitivity on Postoperative Days 3, 7, 14

    Time frame: Day 0 (preoperative) through postoperative Day 14

    Skin sensitivity was measured using Semmes-Weinstein Monofilament set to detect neurological damage. Filament sizes are noted by handle numbers of measuring tools ([handle number = log10(10*force in milligrams applied to skin)], range = 1.65 to 6.65). Detection of filament with smaller handle number = greater skin sensitivity. Smaller change in filament size detection from pre-op to post-op = less impact to recovery of sensation. Smallest filament felt for each side of face was noted. Change in skin sensitivity computed as (Handle Number Postop Day 3, 7, or 14) - (Handle Number Preop Day 0).

  9. Participants' Assessment of Side of Face Preference (SoC and FS VH S/D 4) on Postoperative Days 1, 3, 7, 14

    Time frame: Through postoperative Day 14

    Participants responded to the following question during the side of face preference assessment:

    "Which side of the face do you prefer? Left side, right side, or no preference?"

  10. Proportion of Participants Preferring Either FS VH S/D 4 S-apr or SoC Side of Face - Day 1

    Time frame: Through postoperative Day 1

    Participants responded to the following question during the side of face preference assessment:

    "Which side of the face do you prefer? Left side, right side, or no preference?"

  11. Proportion of Participants Preferring Either FS VH S/D 4 S-apr or SoC Side of Face - Day 3

    Time frame: Through postoperative Day 3

    Participants responded to the following question during the side of face preference assessment:

    "Which side of the face do you prefer? Left side, right side, or no preference?"

  12. Proportion of Participants Preferring Either FS VH S/D 4 S-apr or SoC Side of Face - Day 7

    Time frame: Through postoperative Day 7

    Participants responded to the following question during the side of face preference assessment:

    "Which side of the face do you prefer? Left side, right side, or no preference?"

  13. Proportion of Participants Preferring Either FS VH S/D 4 S-apr or SoC Side of Face - Day 14

    Time frame: Through postoperative Day 14

    Participants responded to the following question during the side of face preference assessment:

    "Which side of the face do you prefer? Left side, right side, or no preference?"

  14. Reasons for Participants' Preferences for Side of Face

    Time frame: Through postoperative Day 14

    Participants responded to the following questions during the side of face preference assessment:

    • "Which side of the face do you prefer? Left side, right side, or no preference?"
    • If "right" or "left" is chosen, participants were asked "Please mark ALL reasons for choosing this side"
    • Better skin sensation
    • Less numbness
    • Looks better
    • Less bruising
    • Less swelling
    • Less pain
    • Less itching
    • Less tingling
    • Less feeling of "pins and needles"
    • Other ________________ (Free Text)

Other outcomes

  1. Participants' Assessment of Difference in Numbness Between Two Sides of Face

    Time frame: Through postoperative Day 14

    During each postoperative visit (Day 1, 3, 7, and 14), participants were asked:

    How would you rate your numbness on each side of your face on a scale of 0-10, with 10 being the worst numbness possible?

    Difference in scores on a scale = (SoC score) - (FS VH S/D 4 s-apr score)

    The planned and approved Statistical Analysis Plan (SAP) called for a pre-aggregation of the data whereby differences between the two sides of the face were computed first within participants to retain the inherent correlation (pairings) in the measures. Summary statistics and statistical tests were then computed on the differences between the two sides of the face using paired sample tests.

  2. Investigator Preference for Side of Face

    Time frame: Through postoperative Day 14

    Investigator reported outcomes data was collected for overall preference for 1 side of face

  3. Investigators' Satisfaction With Quality of Flap Adherence

    Time frame: Through postoperative Day 14

    During postoperative visits investigators recorded their satisfaction with the quality of flap adherence for each side of the face (FS VH S/D 4 s-apr (FS) or Standard of Care (SoC) sides of face)

  4. Investigators' Satisfaction With Rate of Healing

    Time frame: Through postoperative Day 14

    During postoperative visits investigators recorded their satisfaction with the rate of healing of each side of the face (FS VH S/D 4 s-apr (FS) or Standard of Care (SoC) sides of face)

  5. Investigators' Satisfaction With Treatment

    Time frame: Through postoperative Day 14

    During postoperative visits investigators recorded their satisfaction with treatment on each side of the face (FS VH S/D 4 s-apr (FS) or Standard of Care (SoC) sides of face)

  6. Investigators' Confidence in Decreased Postsurgical Complications With the Use of FS VH S/D 4 S-apr

    Time frame: Through postoperative Day 14

  7. Total Aspiration Volumes From Hematomas and Seromas

    Time frame: Through postoperative Day 14

Sponsors and collaborators

Lead sponsor

Baxter Healthcare Corporation

Industry

Registry information

Official study title

A Randomized, Controlled Phase 3 Study to Evaluate Safety and Efficacy of Fibrin Sealant (FS) VH S/D 4 S-apr (ARTISS) to Adhere Tissues and Improve Wound Healing in Subjects Undergoing Rhytidectomy (Facelift)

Important dates

Study start
2009
Primary completion
2009
Study completion
2010
First posted
Oct 21, 2009
Registry last updated
Oct 8, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.